carmustine + cytarabine + thioguanine + cyclophosphamide + hydroxyurea

This item refers to an investigational or non‑standard **multi‑agent chemotherapy combination** consisting of the alkylating nitrosourea carmustine, the antimetabolite nucleoside analog cytarabine, the purine antimetabolite thioguanine, the oxazaphosphorine alkylating agent cyclophosphamide, and the ribonucleotide reductase inhibitor hydroxyurea. These agents are all small‑molecule antineoplastic drugs that damage DNA or disrupt nucleotide synthesis through complementary mechanisms, leading to inhibition of DNA replication and apoptosis in rapidly dividing malignant hematopoietic cells. Variants of overlapping subsets of these drugs (for example carmustine + cytarabine + cyclophosphamide + thioguanine, or cytarabine + thioguanine with cyclophosphamide in other phases of therapy) have been explored historically in high‑risk acute leukemia and related hematologic malignancies, but this exact five‑drug combination does not correspond to a named, widely adopted regimen and would be considered an intensive experimental combination chemotherapy approach.[1][3][4][5][6][7]